Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study. [PDF]
Suzuki K +8 more
europepmc +1 more source
Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer. [PDF]
Ikeda M +8 more
europepmc +1 more source
Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. [PDF]
David K +7 more
europepmc +1 more source
Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients. [PDF]
Lee CH +7 more
europepmc +1 more source
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer. [PDF]
Shore ND +3 more
europepmc +1 more source
LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients. [PDF]
Posocco B +15 more
europepmc +1 more source
Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. [PDF]
Azad AA +9 more
europepmc +1 more source
Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer. [PDF]
Yang Y, Chen YQ, Huang LZ, Chen Y.
europepmc +1 more source
PSMA expression assessed by [<sup>18</sup>F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide. [PDF]
Berg EK +12 more
europepmc +1 more source
Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients. [PDF]
Liu J +5 more
europepmc +1 more source

